Idemitsu Kosan Company, Limited

Nara Institute of Science and Technology

National Institute of Advanced Industrial Science and Technology

National Center for Global Health and Medicine

Hokusan Co. Ltd

Obihiro University of Agriculture and Veterinary Medicine

National University Corporation Nara Institute of Science and Technology

National University Corporation Obihiro University of Agriculture and Veterinary Medicine

Takeshi Matsui

Kazutoshi Sawada

Eiji Takita

Kazuya Yoshida

Akira Ito

Kazuyoshi Koike

Takeshi Matsumura

Noriko Tabayashi

Sou-ichi Makino

Takashi Hamabata

Keiko Kawamoto

Toshio Sato

Sou-Ichi Makino

By linking a peptide tag having the amino acid sequence X(PY)PZ to a protein of interest, and then expressing the protein, the protein of interest is efficiently accumulated in a soluble fraction, where P is proline; X is an amino acid sequence composed of 0 to 5 amino acids independently selected from R, G, S, K, T, L, N, Q, and M; Y is an amino acid sequence composed of 1 to 4 amino acids independently selected from R, G, K, T, L, N, Q, and M; q is an integer 1 to 10; and Z is an amino acid sequence composed of 0 to 10 amino acids independently selected from R, G, S, K, T, L, N, Q, and M; where the amino acid sequence of the peptide tag contains three or more Qs, Ms, Ls, Ns, and/or Ts in total.

Soluble expression of protein using peptide tag

According to the invention, immunogenicity of an antigenic peptide is increased by administering a fusion protein, which comprises an antigenic peptide and an adjuvant protein, wherein the adjuvant protein comprises two or more proteins selected from the group consisting of a Shiga toxin 2e B subunit (Stx2eB), anheat-labile toxin B subunit (LTB), and a cholera toxin B subunit (CTB). or a transformant transformed by a gene coding for the fusion protein.

Vaccine antigen with increased immunogenicity

The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit ofheat-labile toxin.

Vaccine against colibacillosis

The present invention provides an agent for controllingdiarrhea comprising a Shiga toxin as an active ingredient.

[object Object]

A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such asusing the 5'-untranslated region of an alcohol dehydrogenase gene (ADH5&#x2032;UTR) derived from a plant.

Transgenic plants expressing STX2EB protein for use as a pig edema disease vaccine

A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.

Bacterial toxin vaccine

Growing community of inventors

Sodegaura, Japan

Takeshi Matsui